<DOC>
	<DOCNO>NCT01609166</DOCNO>
	<brief_summary>Hand-foot syndrome ( HFS ) dose-limiting toxicity capecitabine effective preventative treatment definitively demonstrate . This trial conduct basis preliminary data 3 % allopurinol-based topical agent may prevent HFS . A randomized , double-blind phase III trial evaluate 40 patient receive first ever cycle capecitabine dose either 2,000 2,500 mg/m2 per day 14 day . Patients randomly assign 3 % allopurinol versus placebo cream , apply hand foot twice per day 6 month start capecitabine . Patients examine every month investigator take photographs hand foot . HFS toxicity grade ( Common Terminology Criteria Adverse Events [ CTCAE ] v3.0 ) also collect baseline end cycle . The primary end point incidence moderate/severe HFS symptom end capecitabine treatment , base patient-reported dermatological exploration .</brief_summary>
	<brief_title>Effectiveness Allopurinol Topical Agent Prevention Capecitabine-induced Hand-foot Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hand-Foot Syndrome</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<criteria>Patients old 18yearsold , initiate treatment oral capecitabine , without sign handfeet syndrome toxicity . Free acceptance participate part clinical trial , signature form inform assent approve study , write volunteer . Age low 18 year Precedents allergy , idiosyncrasy hypersensitivity medicament . Denial patient sign inform assent . Any disorder current / previous treatment , opinion investigator , incapacitate patient take part study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Hand-foot Syndrome</keyword>
	<keyword>capecitabine</keyword>
	<keyword>allopurinol</keyword>
</DOC>